» Authors » Georgios Kosmidis

Georgios Kosmidis

Explore the profile of Georgios Kosmidis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 615
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Aroni A, Detopoulou P, Presvelos D, Kostopoulou E, Ioannidis A, Panoutsopoulos G, et al.
Int J Mol Sci . 2024 Aug; 25(16). PMID: 39201577
Exogenous and endogenous advanced glycation end products (AGEs) contribute to the pathogenesis and progression of renal disease. This is a one-month controlled dietary counseling trial that restricts nutritional AGEs in...
2.
Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F, et al.
Nat Cancer . 2024 Aug; 5(10):1479-1493. PMID: 39179926
The MCL1 gene is frequently amplified in cancer and codes for the antiapoptotic protein myeloid cell leukemia 1 (MCL1), which confers resistance to the current standard of care. Therefore, MCL1...
3.
Campostrini G, Kosmidis G, Ward-van Oostwaard D, Davis R, Yiangou L, Ottaviani D, et al.
Cardiovasc Res . 2022 Apr; 119(1):167-182. PMID: 35394010
Aims: Human-induced pluripotent stem cell-cardiomyocytes (hiPSC-CMs) are widely used to study arrhythmia-associated mutations in ion channels. Among these, the cardiac sodium channel SCN5A undergoes foetal-to-adult isoform switching around birth. Conventional...
4.
Gil A, Kodonis I, Ioannidis A, Nomikos T, Dimopoulos I, Kosmidis G, et al.
Front Oncol . 2022 Feb; 11:810249. PMID: 35127522
Aim: Oleocanthal and oleacein (OC/OL) have important and antitumor properties; however, there is no data about their anticancer activity in humans. The aim of this pilot study was to test...
5.
Guns P, Guth B, Braam S, Kosmidis G, Matsa E, Delaunois A, et al.
J Pharmacol Toxicol Methods . 2020 Jun; 105:106889. PMID: 32565326
Safety pharmacology is an essential part of drug development aiming to identify, evaluate and investigate undesirable pharmacodynamic properties of a drug primarily prior to clinical trials. In particular, cardiovascular adverse...
6.
Aroni A, Zyga S, Tsironi M, Presvelos D, Drakopoulos A, Ralli M, et al.
Cureus . 2020 Jan; 11(12):e6360. PMID: 31938644
Aim The advanced glycation end products (AGEs) are among the mechanisms responsible for the pathogenesis and development of chronic kidney disease. The aim of this study was to estimate the...
7.
Veerman C, Mengarelli I, Lodder E, Kosmidis G, Bellin M, Zhang M, et al.
J Am Heart Assoc . 2017 Jul; 6(7). PMID: 28739862
Background: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) can recapitulate features of ion channel mutations causing inherited rhythm disease. However, the lack of maturity of these cells is considered a...
8.
Devalla H, Gelinas R, Aburawi E, Beqqali A, Goyette P, Freund C, et al.
EMBO Mol Med . 2016 Nov; 8(12):1390-1408. PMID: 27861123
Genetic causes of many familial arrhythmia syndromes remain elusive. In this study, whole-exome sequencing (WES) was carried out on patients from three different families that presented with life-threatening arrhythmias and...
9.
Kosmidis G, Veerman C, Casini S, Verkerk A, van de Pas S, Bellin M, et al.
Circ Arrhythm Electrophysiol . 2016 Oct; 9(11). PMID: 27784737
Background: Several compounds have been reported to induce translational readthrough of premature stop codons resulting in the production of full-length protein by interfering with ribosomal proofreading. Here we examined the...
10.
Birket M, Ribeiro M, Kosmidis G, Ward D, Leitoguinho A, van de Pol V, et al.
Cell Rep . 2015 Oct; 13(4):733-745. PMID: 26489474
Maximizing baseline function of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) is essential for their effective application in models of cardiac toxicity and disease. Here, we aimed to identify factors that...